Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies
Authors
Keywords
-
Journal
Regenerative Medicine
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2023-10-23
DOI
10.2217/rme-2023-0117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study
- (2021) Javier Chavez et al. Stem Cell Research & Therapy
- International stem cell tourism: a critical literature review and evidence-based recommendations
- (2021) Samantha Lyons et al. International Health
- Unproven stem cell interventions: A global public health problem requiring global deliberation
- (2021) Zubin Master et al. Stem Cell Reports
- The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions
- (2021) Leigh Turner Cell Stem Cell
- Adverse events related to unapproved stem cell products and other regenerative interventions: recommendations for more robust regulation of the direct-to-consumer marketplace
- (2021) Farzana Akkas et al. Regenerative Medicine
- Online seminars as an information source for direct-to-consumer stem cell therapy
- (2021) Mirna Hassoun et al. Regenerative Medicine
- Stem-cell clinics in the UK: a web-based study
- (2021) Sami Kamel et al. Regenerative Medicine
- Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer “cell therapy” clinics
- (2021) John W. Hinkle et al. Stem Cell Research & Therapy
- Weighing up the evidence used by direct-to-consumer stem cell businesses
- (2021) Margaret Cook et al. Stem Cell Reports
- Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood–Derived Products Marketed as Stem Cell Therapies
- (2021) Kathleen P. Hartnett et al. JAMA Network Open
- Clear Evidence of Safety and Efficacy Is Needed for Stromal Vascular Fraction Products: Commentary on “Arguments for a Different Regulatory Categorization and Framework for Stromal Vascular Fraction”
- (2020) Peter W. Marks STEM CELLS AND DEVELOPMENT
- Rogue stem cell clinics
- (2020) Iain R. Murray et al. Bone & Joint Journal
- Governmental Regulations and Increasing FDA Oversight of Regenerative Medicine Products: What's New in 2020?
- (2020) William Fang et al. ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY
- Assessing “cell therapy” clinics offering treatments of ocular conditions using direct-to-consumer marketing websites in the United States
- (2019) Rajinder S. Nirwan et al. OPHTHALMOLOGY
- Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years
- (2019) Paul S Knoepfler Regenerative Medicine
- Characterizing Direct-to-Consumer Stem Cell Businesses in the Southwest United States
- (2019) Emma K. Frow et al. Stem Cell Reports
- Direct-to-Consumer Advertising of Stem Cell Clinics
- (2019) Christian A. Pean et al. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
- Online Direct-to-Consumer Advertising of Stem Cell Therapy for Musculoskeletal Injury and Disease
- (2019) Matthew T. Kingery et al. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
- The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis
- (2018) Paul S Knoepfler et al. Regenerative Medicine
- Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites’ marketing of stem cell therapies
- (2018) Blake Murdoch et al. BMJ Open
- Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions
- (2018) Gerhard Bauer et al. Stem Cells Translational Medicine
- Unproven Stem Cell Therapies in India: Regulatory Challenges and Proposed Paths Forward
- (2018) Shashank S. Tiwari et al. Cell Stem Cell
- The deadly business of an unregulated global stem cell industry
- (2017) Tamra Lysaght et al. JOURNAL OF MEDICAL ETHICS
- Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD
- (2017) Ajay E. Kuriyan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Getting Products to Market: Understanding and Navigating the Regulatory Pathway
- (2017) Andrew J. Riff et al. OPERATIVE TECHNIQUES IN SPORTS MEDICINE
- Stem cells in court: historical trends in US legal cases related to stem cells
- (2017) Andreia Martins Martinho et al. Regenerative Medicine
- Marketing of unproven stem cell–based interventions: A call to action
- (2017) Douglas Sipp et al. Science Translational Medicine
- The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective
- (2017) Mitchell Ng et al. Journal of Knee Surgery
- Bilateral Retinal Detachments After Intravitreal Injection of Adipose-Derived ‘Stem Cells’ in a Patient With Exudative Macular Degeneration
- (2017) Steven S. Saraf et al. Ophthalmic Surgery Lasers & Imaging Retina
- Global Distribution of Businesses Marketing Stem Cell-Based Interventions
- (2016) Israel Berger et al. Cell Stem Cell
- Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry
- (2016) Leigh Turner et al. Cell Stem Cell
- The Stem Cell Hard Sell: Report from a Clinic's Patient Recruitment Seminar
- (2016) Paul S. Knoepfler Stem Cells Translational Medicine
- Complication of Autologous Stem Cell Transplantation in Retinitis Pigmentosa
- (2016) Katherine Boudreault et al. JAMA Ophthalmology
- Retinal Detachment After Subretinal Stem Cell Transplantation
- (2016) Ella H. Leung et al. Ophthalmic Surgery Lasers & Imaging Retina
- From bench to FDA to bedside: US regulatory trends for new stem cell therapies
- (2015) Paul S. Knoepfler ADVANCED DRUG DELIVERY REVIEWS
- US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions
- (2015) Leigh G Turner Regenerative Medicine
- Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine
- (2015) Celia M. Witten et al. Stem Cells Translational Medicine
- Governing stem cell therapy in India: regulatory vacuum or jurisdictional ambiguity?
- (2014) Shashank S. Tiwari et al. NEW GENETICS AND SOCIETY
- Representations of Stem Cell Clinics on Twitter
- (2014) Kalina Kamenova et al. Stem Cell Reviews and Reports
- Stem cell tourism – A web-based analysis of clinical services available to international travellers
- (2014) Ruairi Connolly et al. Travel Medicine and Infectious Disease
- Reassessing direct-to-consumer portrayals of unproven stem cell therapies: is it getting better?
- (2013) Ubaka Ogbogu et al. Regenerative Medicine
- Direct-to-Consumer Stem Cell Marketing and Regulatory Responses
- (2013) Douglas Sipp Stem Cells Translational Medicine
- China’s stem-cell rules go unheeded
- (2012) David Cyranoski NATURE
- The unregulated commercialization of stem cell treatments: a global perspective
- (2011) Douglas Sipp Frontiers of Medicine
- Tracking the rise of stem cell tourism
- (2009) Kirsten A Ryan et al. Regenerative Medicine
- MEDICINE: Monitoring and Regulating Offshore Stem Cell Clinics
- (2009) S. Kiatpongsan et al. SCIENCE
- Medicine on the Fringe: Stem Cell-Based Interventions in Advance of Evidence
- (2009) Alan C. Regenberg et al. STEM CELLS
- Stem Cell Clinics Online: The Direct-to-Consumer Portrayal of Stem Cell Medicine
- (2008) Darren Lau et al. Cell Stem Cell
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More